Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
No results matched your search
Amgen Inc (AMGN)
NASDAQ
| Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| AMGN | NASDAQ | USD | Real-time | |
| AMGN | Mexico | MXN | Delayed | |
| AAMGN | Milan | EUR | Real-time | |
| AMGN | TradeGate | EUR | Delayed | |
| AMGN | Frankfurt | EUR | Delayed | |
| AMGN | Xetra | EUR | Delayed | |
| AMGN | Buenos Aires | ARS | Delayed | |
| AMGN34 | BM&FBovespa | BRL | Delayed | |
| 4332 | Hong Kong | HKD | Delayed | |
| AMGN | Vienna | EUR | Delayed |
Add to/Remove from a Portfolio
Add to Portfolio
224.92
-2.60
-1.14%
After Hours
224.92
0.00
0.00%
0:44:40 - Real-time Data
- Volume: 3,453,588
- Bid/Ask: 224.40 / 225.00
- Day's Range: 223.62 - 230.31
Amgen
224.92
-2.60
-1.14%
- General
- Chart
- News & Analysis
- Financials
- Technical
- Forum
- Overview
- Profile
- Historical Data
- Options
- Index Component
Prev. Close227.52
Day's Range223.62 - 230.31
Revenue25.42B
Open230.31
52 wk Range177.05 - 276.69
EPS12.31
Volume3,453,588
Market Cap129.91B
Dividend (Yield)7.04 (3.09%)
Average Volume (3m)2,495,641
P/E Ratio18.26
Beta0.71
1-Year Change12.61%
Shares Outstanding577,566,383
Next Earnings DateApr 28, 2021
What is your sentiment on Amgen?
Members' Sentiments:
or
Market is currently closed. Voting is open during market hours.
Amgen Inc News
AstraZeneca and Amgen's tezepelumab successful in phase 3 for severe asthma
By Seeking Alpha - Feb 26, 2021
AstraZeneca and Amgen have released full phase 3 results of the biologic tezepelumab in severe asthma patients that showed significant reductions in asthma exacerbation rate.
Amgen submits Otezla plaque psoriasis marketing application to the FDA
By Seeking Alpha - Feb 22, 2021
The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal
By Benzinga - Feb 17, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 16) 10X Genomics Inc (TXG) 9 Meters...
Amgen Inc Analysis
Amgen Inc. 2020 Q4 - Results - Earnings Call Presentation
By Seeking Alpha - Feb 03, 2021
'How Can I Be Up If The Market Goes Down?' Isn't The Right Question To Ask
By Joseph L. Shaefer - Dec 01, 2020
This article was written exclusively for Investing.com Or, conversely, "How can I be down when the market is up?" Clients have asked me both questions and the answer is the same...
Technical Summary
| Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Sell | Strong Sell | Buy |
| Technical Indicators | Neutral | BUY | Strong Sell | Strong Sell | Neutral |
| Summary | Sell | Neutral | Strong Sell | Strong Sell | Neutral |
Filter Table By:
| Pattern | Timeframe | Reliability | Candles Ago | Candle Time | |
|---|---|---|---|---|---|
| Emerging Patterns | |||||
| Engulfing Bearish | 15 | Current | |||
| Engulfing Bearish | 1M | Current | |||
| Completed Patterns | |||||
| Falling Three Methods | 1H | 2 | Feb 26, 2021 19:00 | ||
| Three Inside Up | 30 | 2 | Feb 26, 2021 20:30 | ||
| Engulfing Bearish | 15 | 2 | Feb 26, 2021 21:15 | ||
Amgen Inc Quotes
| Exchange | Last | Bid | Ask | Volume | Change % | Currency | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| NASDAQ | 224.92 | 224.40 | 225.00 | 3,453,588 | -1.14% | USD | 26/02 | ||
| Mexico | 4,688.50 | 0.00 | 0.00 | 0 | 0.00% | MXN | 24/02 | ||
| Milan | 184.92 | 0.00 | 0.00 | 118 | -1.38% | EUR | 26/02 | ||
| TradeGate | 186.76 | 186.48 | 187.20 | 2,200 | +0.13% | EUR | 26/02 | ||
| Frankfurt | 185.00 | 0.00 | 0.00 | 186 | -1.48% | EUR | 26/02 | ||
| Xetra | 185.44 | 185.10 | 185.42 | 1,322 | -0.69% | EUR | 26/02 | ||
| Buenos Aires | 3,316.000 | 0.000 | 0.000 | 445 | -1.26% | ARS | 26/02 | ||
| BM&FBovespa | 44.99 | 44.50 | 45.73 | 53,176 | +0.60% | BRL | 26/02 | ||
| Hong Kong | 1,761.00 | 1,761.00 | 0.00 | 0 | 0.00% | HKD | 11/02 | ||
| Vienna | 183.400 | 0.000 | 0.000 | 255 | -1.64% | EUR | 21/12 |
Trending Stocks
| Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| Guaranty Trust Bank | 31.00 | 31.10 | 31.00 | -0.05 | -0.16% | 9.02M | 26/02 | ||
| Dangote Cement | 207.40 | 207.40 | 207.40 | -12.60 | -5.73% | 174.98K | 26/02 | ||
| Zenith Bank | 25.45 | 25.90 | 25.30 | -0.40 | -1.55% | 26.61M | 26/02 | ||
| UBA | 8.15 | 8.35 | 8.00 | -0.05 | -0.61% | 16.09M | 26/02 | ||
| FBN Holdings | 7.35 | 7.40 | 7.30 | +0.00 | +0.00% | 30.75M | 26/02 | ||
| Fidson | 5.000 | 5.000 | 5.000 | +0.100 | +2.04% | 192.99K | 26/02 | ||
| UPDC REIT | 5.35 | 5.35 | 5.35 | -0.50 | -8.55% | 28.64K | 26/02 | ||
| 7Up | 107.06 | 107.06 | 107.06 | 0.00 | 0.00% | 0 | |||
| Access Bank | 8.25 | 8.25 | 7.95 | +0.15 | +1.85% | 12.38M | 26/02 | ||
| Champion Brew | 2.52 | 2.53 | 2.52 | -0.28 | -10.00% | 601.88K | 26/02 |
Amgen Inc Company Profile
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
Read More
Write your thoughts about Amgen Inc
Are you sure you want to delete this chart?
Delete Cancel
Replace the attached chart with a new chart ?
Replace Cancel
Comment Guidelines
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.